Glioblastome
L’analyse de marché MabDesign de ce mois-ci vous donne un aperçu de la dynamique marché et des projets en développement ciblant le traitement du glioblastome.
Exosomes and extracellular vesicles
Long considered as cellular debris with no biological function, exosomes, and more generally extracellular vesicles (EVs), are now recognized as vectors of biological material with a role in intercellular communication. The building of knowledge on the subject has not only highlighted their role in certain pathologies, but also revealed their potential as biomarkers and therapeutic tools.
Anticorps bispécifiques
L’analyse de marché MabDesign de ce mois-ci vous donne un aperçu de la dynamique marché et des anticorps bispécifiques en développement.
Melanoma
This month’s MabDesign market analysis gives you an overview of market dynamics and development projects targeting melanoma treatment.
Cell and gene therapies
The first edition of our Innovations for Cell and Gene Therapies (ICGT) congress, organized in collaboration with the Société Française de Thérapie Cellulaire et génique (SFTCG), will take place on May 22, 2024, in Paris. In the meantime, this month we share an overview of the cell and gene therapy market.
Advanced therapy medicinal products: from the lab to the patient’s bed
Advanced therapy medicinal products (ATMPs) explore new therapeutic approaches based on genome modification, manipulation of patient or healthy donor cells and other innovative methods, representing a major transition from traditional medicine to more personalized and targeted medicine.
The history of biologics: from discovery to therapeutic revolution
Biopharmaceuticals, or biotherapies, are becoming increasingly important on the market, and offer immense hope for the treatment of many diseases. From the first discoveries of vaccines to the recent development of cell and gene therapies and regenerative medicine, looking back at biologics’ history lets us have a better understanding of the revolution that they provoked in the pharmaceutical industry and in modern medicine .
Therapeutic vaccines in oncology
This month, MabDesign’s market analysis provides an overview of the market for therapeutic oncology vaccines.
antibody-drug conjugates
This month’s MabDesign market analysis gives you an overview of the antibody-drug conjugates market and projects in development.
Prophylactic or Therapeutic : what does the future hold for vaccines ?
Fuelled by decades of innovation, vaccines are an essential tool in the fight against disease. Historically focused on prophylaxis to prevent the spread of infectious diseases, new generations of vaccines are now being developed and/or are already available in other therapeutic areas including oncology. Historically focused on prophylaxis and infectious diseases, they are now opening up to new avenues of development, with a range of vaccine technologies, the positioning of vaccines as a new therapeutic tool, and the opening up of other therapeutic areas such as oncology.
Monoclonal antibodies: the stars of therapeutic proteins
Hybridoma technology for the production of monoclonal antibodies (mAbs), awarded the Nobel Prize for Medicine in 1984, revolutionized serotherapy, which previously used patient serum containing mixtures of antibodies. More targeted and therefore more effective, mAbs offer innovative perspectives in the treatment of various diseases, and have become an essential therapeutic strategy in our pharmaceutical arsenal.
Neurological disorders
This month’s market analysis by MabDesign gives you an overview of market dynamics and projects in development targeting neurological disorders.
